Ohe Go, Kudo Yasusei, Kamada Kumiko, Mouri Yasuhiro, Takamaru Natsumi, Kudoh Keiko, Kurio Naito, Miyamoto Youji
Department of Oral Surgery, Tokushima University Graduate School, 3-18-15 Kuramoto-cho, Tokushima 770-8504, Japan.
Dentistry and Oral Surgery, Takamatsu Municipal Hospital, 847-1 Ko Busshozan-cho, Takamatsu 761-8538, Japan.
Cancers (Basel). 2021 Jun 30;13(13):3301. doi: 10.3390/cancers13133301.
(1) Background: OK-432 is a penicillin-killed, lyophilized formulation of a low-toxicity strain (Su) of (Group A). It is a potent immunotherapy agent for several types of cancer, including oral cancer. We previously showed that (i) OK-432 treatment induces a high amount of IFN-? production from peripheral blood mononuclear cells (PBMCs), and (ii) conditioned medium (CM) from oral cancer cells suppresses both the IFN-? production and cytotoxic activity of PBMCs driven by OK-432. The aim of this study was to determine the inhibitory mechanism of OK-432-induced IFN-? production from PBMCs by CM. (2) Methods: We performed cDNA microarray analysis, quantitative RT-PCR, and ELISA to reveal the inhibitory mechanism of CM. (3) Results: We found that CD40 plays a key role in IFN-? production via IL-12 production. Although OK-432 treatment upregulated the expression levels of the , , and genes, CM from oral cancer cells downregulate these genes. The amount of IFN-? production by OK-432 treatment was decreased by an anti-CD40 neutralizing antibody. (4) Conclusions: Our study suggests that uncertain soluble factor(s) produced from oral cancer cells may inhibit IFN-? production from PBMCs via suppressing the CD40/CD40L-IL-12 axis.
(1) 背景:OK-432是A组低毒力菌株(Su)经青霉素灭活后的冻干制剂。它是多种癌症(包括口腔癌)的一种有效的免疫治疗药物。我们之前表明:(i)OK-432处理可诱导外周血单个核细胞(PBMCs)产生大量干扰素γ;(ii)口腔癌细胞的条件培养基(CM)可抑制OK-432驱动的PBMCs的干扰素γ产生及细胞毒性活性。本研究的目的是确定CM对OK-432诱导PBMCs产生干扰素γ的抑制机制。(2) 方法:我们进行了cDNA微阵列分析、定量逆转录聚合酶链反应和酶联免疫吸附测定以揭示CM的抑制机制。(3) 结果:我们发现CD40在通过白细胞介素1(IL-12)产生干扰素γ的过程中起关键作用。虽然OK-432处理上调了CD40、CD40配体(CD40L)和IL-12基因的表达水平,但口腔癌细胞的CM下调了这些基因。用抗CD40中和抗体可降低OK-432处理所产生的干扰素γ量。(4) 结论:我们的研究提示,口腔癌细胞产生的未知可溶性因子可能通过抑制CD40/CD40L-IL-12轴来抑制PBMCs产生干扰素γ。